These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

686 related articles for article (PubMed ID: 16117974)

  • 1. Anidulafungin: a new echinocandin with a novel profile.
    Vazquez JA
    Clin Ther; 2005 Jun; 27(6):657-73. PubMed ID: 16117974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anidulafungin: a novel echinocandin.
    Vazquez JA; Sobel JD
    Clin Infect Dis; 2006 Jul; 43(2):215-22. PubMed ID: 16779750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Echinocandins: the newest class of antifungals.
    Sucher AJ; Chahine EB; Balcer HE
    Ann Pharmacother; 2009 Oct; 43(10):1647-57. PubMed ID: 19724014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The echinocandins.
    Cappelletty D; Eiselstein-McKitrick K
    Pharmacotherapy; 2007 Mar; 27(3):369-88. PubMed ID: 17316149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anidulafungin pharmacokinetics and microbial response in neutropenic mice with disseminated candidiasis.
    Gumbo T; Drusano GL; Liu W; Ma L; Deziel MR; Drusano MF; Louie A
    Antimicrob Agents Chemother; 2006 Nov; 50(11):3695-700. PubMed ID: 16954319
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacology and antifungal properties of anidulafungin, a new echinocandin.
    Estes KE; Penzak SR; Calis KA; Walsh TJ
    Pharmacotherapy; 2009 Jan; 29(1):17-30. PubMed ID: 19113794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The echinocandins: comparison of their pharmacokinetics, pharmacodynamics and clinical applications.
    Wagner C; Graninger W; Presterl E; Joukhadar C
    Pharmacology; 2006; 78(4):161-77. PubMed ID: 17047411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anidulafungin in the treatment of patients with invasive candidiasis.
    Kett DH; Cubillos GF
    Int J Antimicrob Agents; 2008 Nov; 32 Suppl 2():S99-S102. PubMed ID: 19013348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micafungin: a new echinocandin antifungal.
    Joseph JM; Jain R; Danziger LH
    Pharmacotherapy; 2007 Jan; 27(1):53-67. PubMed ID: 17192162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anidulafungin versus fluconazole for invasive candidiasis.
    Reboli AC; Rotstein C; Pappas PG; Chapman SW; Kett DH; Kumar D; Betts R; Wible M; Goldstein BP; Schranz J; Krause DS; Walsh TJ;
    N Engl J Med; 2007 Jun; 356(24):2472-82. PubMed ID: 17568028
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anidulafungin: a new echinocandin for candidal infections.
    de la Torre P; Reboli AC
    Expert Rev Anti Infect Ther; 2007 Feb; 5(1):45-52. PubMed ID: 17266452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anidulafungin, a new echinocandin: effectiveness and tolerability.
    Menichetti F
    Drugs; 2009; 69 Suppl 1():95-7. PubMed ID: 19877741
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micafungin.
    Carver PL
    Ann Pharmacother; 2004 Oct; 38(10):1707-21. PubMed ID: 15340133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Echinocandins in invasive candidiasis].
    Glöckner A; Cornely OA
    Med Klin (Munich); 2008 Jun; 103(6):397-405. PubMed ID: 18548209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species.
    Karlowsky JA; Hoban DJ; Zhanel GG; Goldstein BP
    Int J Antimicrob Agents; 2006 Feb; 27(2):174-7. PubMed ID: 16414247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echinocandin use in the neonatal intensive care unit.
    Caudle KE; Inger AG; Butler DR; Rogers PD
    Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activity of amphotericin B, anidulafungin, caspofungin, micafungin, posaconazole, and voriconazole against Candida albicans with decreased susceptibility to fluconazole from APECED patients on long-term azole treatment of chronic mucocutaneous candidiasis.
    Rautemaa R; Richardson M; Pfaller MA; Perheentupa J; Saxén H
    Diagn Microbiol Infect Dis; 2008 Oct; 62(2):182-5. PubMed ID: 18597968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.